EFTA00299765.pdf

BioRe ference LABORATORI ES FINAL REPORT Sr OFVCCIHealth Company rPsTEIN, 7EFFREY Specimen IR: 104659439 D08: 81/28/1953 Age: 64 y Sex: m Date Of Report: 89/21/2017 10:08 U/FL: Bed: S Rm: A Date Collected: 09/15/2017 08:57 Date Received: 09/15/2017 23:06 Patient ED: 0 Address:9 EAST 715T STREET, NEW YORK, MY 10021 11: 1. North America Eastern Ttnie I Nores: NCN FASTING NOTE: SST tube submitted was inadequatel y spun. Serum was found to contain RBCs. Certain tests, e.g. Glucose, may be decreased while others e.g. Potassium or LOH may be elevated. CLINICAL REPORT Clinical Abnormalities Summary: rmay not contain all abnormal results; narrative results may not have abnormal flags. Please review entire report.) Cholesterol 224 HI Triglycerides 646 HI ROL CHOL., DIRECT 29 LO HDL as % of 13 • Choi/HDL Ratio 7.7 • NON-HDL 195 HI Cholesterol CHOLESTEROL HEP. A Ab., TOTAL Reactive * HEP. H SURF. AR. Reactive • 250H, VITAMIN D 31.5 LO PTH(3), INTACT 196.9 HI PNEUMO Ab TYPE 1 0.3 LO PNEUMO Ab TYPE 4 8.8 LO (58) (58) PNEUMO Ab TYPE 8 0.6 LO PNEUMO Ab TYPE 9 (9N) 8.7 LO PNEUMO Ab TVPE 12 (12F) (58) (58) (58) PNEUMO Ab TYPE 19 (19F) 1.1 LO PNEUMO Ab TYPE 23 (23F) 0.3 LD PRELIM° Ab TYPE 26 (68) 8.9 LO (58) (58) (58) PNEUMO Ab TYPE 68 (9V) 9.5 LO B.Henselae IgG Ab 1:64 • (58) (3) Albumin 4.7 3.5.5.2 g/dL 4.5 08/30/1017 .Calcium 9.8 8.6-12.4 Ing/ill• • 9.7 30 - -* CARDIOVASCULAR/LIPIDS *-- cholesterol 224HI <200 mg/dL 226 HI 8/30/2017 Triglycerides 646 MI <Ise :mg/dL IS29 Mt 8E/80/2017 BBL 0440L'eroEcr . 29 LO >40 mg/a TNP 08/39iidij . HDL es t.0 Choles —11-1--- >14 yNp 08/30/2017 Evaluation: ABOVE AVG.(OWDERATE RISK) Ratio 7.7 a <7.4 • avaiiiiii7 •-• •. Evaluation: ABM AVO.(MODERATE RISK) to HDL Ratio 7.-- - com et:MR- Aa, tote- ot/30/2e0 i98 MI 4136 mg/dL ELbranCeitiirer <lee esini2015 44041:. uoioto to coiculate.m. due to a Triglycerido level of greater tton 408 Ii/dL. , • • " VLDL, CALCULATED Can't Calm 7-32 mg/di (._.Can't CaLc 108/39/2017 ...._... . •-- BioReference Laboratories, Inc. James Weisberger M.D. Page 1 of 481 Edward H. Ross Dr I Elammod Park, NO B7407 I Laboratory Director 'rioted ,i 9/22/2917 89:57 EFTA00299765  Bio LAB Ref oRA ere ToR nce i Es an OPKO Health Company FINAL REPORT ORSHER, STUART EPSTEIN, JEFFREY Specimen ID: 104659439 DOB: 01/20/1953 Age: 64 y Sex: m U C3870 - STUART ORSHER, U/FL: Date Of Report: 09/21/2017 10:88 N.D. Bed: 9 EAST 79TM 5T, Na: a Date Collected: 09/15/2017 88:57 Date Received: 09/15/2017 23:06 Patient ID: NEW YORK, NY 10021 Address:9 EAST 71ST STREET, p Acct #: (C3070) MO NEW YORK, HY 10021 P: E North Americo Eastern Time CLINICAL REPORT Can't Calc: One or more components was outside the measurable range. We are unable to calculate. --* MISCELLANEOUS T5H 1.770 0.178-4.530 uIU/aIL TNP 08/30/2017 7.3 4.9-12.9 ill UPTAKE (13U) ug/dL TNP 08/30/2017 31.0 24.3-39.0 rffirmodat, FREE (aT4Y • 3.11 TNP 08/30/2017 — 6710--1.71r ng/d1 TNP : FREE T4 INDEX . . 08/30/2017 • 2.3 1.5-3.8 1T3 (THYRONINE), TOTAL TNP 98/30/2017 127 -180 HEP: A Ab:,. -IgM r&dL --14NP B/30/1017 • Non- Non-Reactive .•• .• Reactive NOTE: Hep A Ab,IgM is positive or reacti ve during the acute phase. Hep A Ab/Total is positive or reacti ve during the recovery phase or is indicative of a past infection. ; MEP. B CORE Ab. I66 • Non- -Non-Reactive TNP 88/30/2017 Non-Reactive TAP . 08/30/2017 Reactive Ramage • Na7kaaifive B SURF. A4 TNP BB/30/2917 • tioh- Non-Reactive Reactive eaftifidi7 • NEP. IT-417' Negative legative 88/30/2017 BE AO.- Negative • Negative • 08/30/2017 WTOSTERDNE; TOT.,S: 194.3 193.44463---- 018/10/1017 NOTE: Patients receiving the drug Nandrolone cannot be tested for TESTOSTERONE, total using the EIA method (test code 0379-8) due to a strong interference from the drug. Clinic ians are asked to request Testosterone, Total by LC/H5/ MS (test code )4516) for these Patients. gii Nakk.RiN15.0. .6e. 14 10-57 nmol/L 'tl.e4 30.00-150.00 pg/mL LH 3.8 1.74.6 mIU/mi Ci 280 i ll QUINTANA AB 6/N (30 39-308 Q/L 08/362017 s€t BELOW ' B. quintana Ab, IgM . < 2:16 --INTERPRETIVE INFORMAT/ON: Bartonella Quintana Ab, lgm -- Less than 1:16 Negative-No significant level of .... . . BioReference Laboratories, Inc. 481 Edward R. Ross Dr I Elmwood Park. NJ James Weisberger M.D. Page 2 of 5 07407 t Laboratory Director Printed 09/22/2017 09:57 EFTA00299766  13ioReference LASORATOR/ES FINAL REPORT an OPKO Health Company ORSHER, STUART EPSTEIN, JEFFREY Specimen ID: 104659439 DOB: 01/20/1953 Age: 64 y Sex: C3070 - STUART ORSHER, M.O. H Date Of Report: 89/21/2017 10:08 U/FL: Bed: S Date Collected:09/15/2817 88:57 Rm: A 9 EAST 79TH 57, ate Received: 09/15/2017 23:06 Patient ID: NEW YORK, NY 10021 Address:9 EAST 71ST STREET, p Acct a: (C3070) NEW YORK, NY 10821 L P. North Americo Eastern Time Bartonel a quintana IgN antibody detected. 1:16 or greater Positive-Presence of IgM antibody to Bartonella quintana detected, suggestive of current or recent infection. --The presence of 1.0( antibodies sugges ts recent infection. Low --levels of IgM antibodies may occasionally persist for more than 12 . --months post-infection. --Test developed and characteristics determ ined by ARUP --Laboratories. See Compliance Statement A: aruplab.com/CS --www.aruplab.com, Julio Delgado, MD - Lab. Director B. quintana Ab, Ig6 <1:64 --INTERPRETIVE INFORMATION: ilartonella quinta na Antibody, IgG -- Less than 1:64 Negative: No significant level of Bartonella quintana Ig6 antibody detected. 1:64 - 1:128 Equivocal: Questionable presence of Bartonella quintana Ig6 antibody detected. Repeat testing in 20-14 days may be helpful. 1:256 or greater Positive: Presence of IgG antibody to Bartonella quintana detected, suggestive of current or past infection. --A low positive suggests past exposure or infect ion, while high --positivB reSUltS may indicate recent or current infect ion, but is --inconclusive for diagnosis. Seroconversion betwee n acute and --convalescent sera is considered strong evidence of recent --infection. The best evidence for infection is a significant change --on two.appropriately timed specimens where both tests are done in --the same laboratory at the same time. --Test developed and characteristics determined by AK, i --Labo ratories. See Compliance Statement A: aruplab.con/CS 'HEP. C Ab. Non- Non-Reactive VIP ML*( NEPCA5CCORAne (314 : performed .by: fIRU7 . Reactive 0.03 0.80 MP . I • 08/30/2017 SOO Chipeta Way. Salt Lake City, UT 841011 Hepatitis 8 Result Interpretation (for reference. use only) Master il/EAs Acute Oast Chronic IMV • atessamilmit eat + t - .t SioReference Laboratories, Inc. 481 Edward H. Ross Dr I Elmwood Park, N3 07487 JainesWelabargeril.D. Page 3 of 5 Laborator/Director Printed 09/22/2917 09:57 EFTA00299767  BioReference LABORATOR I ES FINAL REPORT an OPKOHealth Company mom, STUART EPSTEIN, 7EFFREY Specimen ID: 18404430 D DOB: 01/20/1963 Age: 64 V Sex: e Date Of Report: 09/21/2017 10:08 a C3070 - STUART ORSHER, N.D. U/FL: Bed: ate Collected: 09/15/2017 08:57 R Ie: 9 EAST 791N ST, Date Received: 40/13/2017 23:06 Patient ID: EA YORK, NY 10021 Address:9 EAST 11ST STREET, r. cct 8: (C3070) MO NEW NUFK, Pe 10821 P: P: I II Atrit, AmPrica fs5terr mBeAg +- HEP.B.CORE AB,IgM HEP.B.CORE AB. + N8eAb +/- +/. MBSAb +/- "Late Incubation/Early Acute . NOTE: In remote past infection, HBsAb level may be Negative or Mon-Reactive in Some patients. ACID 7.77 >5.38 ng/oL tep 040/241i : Folic Acid Range Units (ng/eL) Weal >5.38 Borderline deficient 3.38-5.38 Deficient 0.35-3.37 EXCe8Sive >24.00 : 114114exitil 359 niaar Tip- ,2SON, VITAMIN 0 •- "." 'heir ' '" VITAMIN 0,25-0H TEST INFORMATION Range (ng/mL) Suggested Interpretation <20.8 Deficient 20.0-31.9 Insufficient 32.0-100.0 Sufficient >100.0 Possible Adverse Effects Tgrolasobwo0dict . ..... 52.8 ' ii7iciic5-----'-iiiii7 I.... n.77 1WW-- IPTH(3), INTACT 14/31755ii- 106.0 HI i3.1:44.8-. nenL " -- 71143 0/36/2817-, :PERM Ablwq 1 (58) 0.3 LO 51.3 . ug/fiL (0.3 D 08/30/2017 ANEUMO Ab TYPE 3 (58). 1.8 1.---__,,-,__...... >1.3 ' ' Ug/iL 1.4 08/3e/2017 mum AD TYPE nal .. 0.8 LO cCI-- . Ug/IL .. 9.6 L BB/38/ 8i7 PRES Ab TYPE 8 (58) -. 0.6 tO >2.3 Ug/mi ' 4:4 LO ' 08/30/24317 — Th iani i firi 9 (48) (se) 0.7 LO >4.1 ' • UgieL: /30/2817 POOSo-An DOELi-(11O)(41)"' - 4.1 L0 >1:3 ' -6024L. 08/30/2017 NEUMD Ab TYPE 14 010 7---' >it.3 >1.3 Wet 23.2 08 30/1017 TPNEUNO Ab TYPE 19 (19F) (58) ' 1.1 L0 ii:i -. ueini - 9.8 to 00/30/2017 WOW -a TYPE 10 (20)(037— Ira >1.3 . 4717 8 - i t'0.3 LO Os/ /2817 pwuko Ab TYPE 26 (GB) (58) 8.4 LO )1.3 wi/wL ti.s tO 08/3e/2017 - iiPECIMO Ab TYPE 5 8.i--- . ... ...... >1.3 48/71C pili(446 6 WOE if(10j .(34)- — I:4 • ...'≥LS' ug/iL 1.5 08/30/2017 -0140413743T*E - T6-titC71413- 1.8 >1.3 80/0 • I.3 0 --- beWeifrozl . meupb At; TYPE 66 (9w) ( 51). • • 0.0 Lo . . i1:3 - ug/nL 4:4 io 08/30/2017 • ......_ *This test was developed and its performance characteris tics determined by bloaelerence Laboratories, Inc. JanemONebelmwDereeD. Page 4 of 5 481 Edward H. Ross Dr I Elmwood Park, 83 07407 Laboratory okootor Printed 49/22/2027 09:57 EFTA00299768  Bio Reference sORATORIEs en Orlin" Health FINAL REPORT Company WISNER, STUART (EPSTEIN, 3EFFREY Specimen ID: 104659439 DOD: 01/20/1953 Age: 64 Y Ser: M [3070 - STUART ORSHER, M.D. Date Of Report: 09/21/2017 10:08 Red: S Date Collected: 09/15/2817 04:S7 A 9 EAST 79TH ST, Date Received: 09/15/2017 23:0S Patient ID: 0 NEW YORK, NY 184321 Address:9 EAST 71ST STREET, Acct #: (C3078) MD NEN YORK, NY 10821 P: E P: North America Eastern Tier CLINICAL REPORT I Viracor EurofinS. It as no, teen " • . 4.-4,: ••• • • • •• • ••••••It • i• "41.1 • '•• ••• ••'• .•'•• • " clear? or aPPrOve . Drug Administration. Testing Performed At: Viracor Eurofins 1001 NW Technology Drive . Lee's Summit, MO 64886 IIIMM CLIM ESI 643 e.11eitflfliekid Ab (3) 1:64 • piiieriieile l`gM Ab (3) titer 1:64 g '08/30/aiii'l. <1:20 • ie •••• • -••• • titer <1:20 08/30/2017 • This test was developed and its analyt ical performance characteristics have been determined by Quest Diagnostics Nichols Institute Valencia. It has not been cleared or approved by the US Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes. (3) Performed by: Quest Diagnostics Nichols Institute of Valencia 27027 Tourney Road Valencia, CA 9135S-5386 (S8) Performed by: viracor Eurofins Clinical Diagnostic 1001 NW Technology brive Lees Summit, MO 64086 NOTE: Specimen submitted is LIPEMIC. This may cause inaccurate rnsults. Please resubmit a fasting specimen at your earliest convenience. SioReference laboratories, Inc. 481 Edward R. Ross Or I Elmwood Park, NJ 07407 l James Weisberger M.D. Page 5 of S LaboretopylDkeclor Printed 09/22/2017 09:57 EFTA00299769